Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $260,375.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company’s stock, valued at $20,629,865.36. This represents a 1.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Enliven Therapeutics Trading Up 0.8 %

Shares of ELVN opened at $21.08 on Friday. The business’s 50-day moving average price is $21.31 and its 200 day moving average price is $23.76. The stock has a market capitalization of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. On average, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently bought and sold shares of ELVN. Tower Research Capital LLC TRC boosted its position in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $97,000. BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $112,000. ExodusPoint Capital Management LP acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $200,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $228,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ELVN. BTIG Research began coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. HC Wainwright raised their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $38.75.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.